Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,948
  • Shares Outstanding, K 60,965
  • Annual Sales, $ 1,560 K
  • Annual Income, $ -62,680 K
  • 60-Month Beta -0.01
  • Price/Sales 11.76
  • Price/Cash Flow N/A
  • Price/Book 0.55
Trade LYRA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.13
  • Most Recent Earnings $-0.29 on 08/14/24
  • Next Earnings Date 11/05/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 60.77%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,087.61% on 08/21/24
  • IV Low 0.00% on 09/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 4,725
  • Open Int (30-Day) 4,361

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.26
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +14.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2546 +7.50%
on 09/11/24
0.3426 -20.11%
on 08/26/24
-0.0250 (-8.37%)
since 08/16/24
3-Month
0.2532 +8.10%
on 06/27/24
0.3440 -20.44%
on 08/06/24
+0.0149 (+5.76%)
since 06/18/24
52-Week
0.2532 +8.10%
on 06/27/24
6.7900 -95.97%
on 03/27/24
-4.2963 (-94.01%)
since 09/18/23

Most Recent Stories

More News
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company, Lyra or Lyra Therapeutics), a clinical-stage therapeutics company leveraging its...

LYRA : 0.2737 (-1.55%)
LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform...

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)("Lyra" or the "Company"), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢...

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform to enable precise,...

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform to enable precise,...

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform to enable precise,...

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis...

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role

LYRA : 0.2737 (-1.55%)
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreoâ„¢ Technology Platform in the American Journal of Rhinology & Allergy

Results demonstrate XTreo â„¢ technology platform provides targeted and sustained dosing of anti-inflammatory medication

LYRA : 0.2737 (-1.55%)

Business Summary

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and...

See More

Key Turning Points

3rd Resistance Point 0.2980
2nd Resistance Point 0.2924
1st Resistance Point 0.2831
Last Price 0.2737
1st Support Level 0.2682
2nd Support Level 0.2626
3rd Support Level 0.2533

See More

52-Week High 6.7900
Fibonacci 61.8% 4.2929
Fibonacci 50% 3.5216
Fibonacci 38.2% 2.7503
Last Price 0.2737
52-Week Low 0.2532

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar